SILVERBACK THERAPEUTICS INC (SBTX) Stock Analyst Earnings Estimates
NASDAQ:SBTX - Nasdaq - US82835W1080 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A | |||||
| EBITDA YoY % growth | -17.84M | -23.53M -31.89% | -32.28M -37.19% | -88.801M -175.10% | N/A 21.75% | N/A -4.50% | N/A -3.50% | N/A 3.92% | N/A 0.40% | |
| EBIT YoY % growth | -18.32M | -24.07M -31.39% | -32.92M -36.77% | -89.584M -172.13% | N/A 25.23% | N/A -10.37% | N/A -5.75% | N/A 9.86% | N/A 8.06% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -2.56 -10.08% | N/A 26.29% | N/A -10.81% | N/A -4.88% | N/A 9.65% | N/A 7.84% |
All data in USD
| Q4 / 22 | |
|---|---|
| EPS Q2Q % growth | -0.35 47.48% |
| Revenue Q2Q % growth | |
| EBITDA Q2Q % growth | N/A |
| EBIT Q2Q % growth | -12.491M 46.86% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2022 Q2Q % growth | -0.55 21.43% | -0.49 | -0.06 | -11.56% |
| Q1 2022 Q2Q % growth | -0.70 -29.63% | -0.55 | -0.15 | -28.04% |
| Q4 2021 Q2Q % growth | -0.67 51.09% | -0.72 | 0.05 | 6.43% |
| Q3 2021 Q2Q % growth | -0.65 | -0.69 | 0.04 | 5.45% |
| Q2 2021 Q2Q % growth | -0.70 | -0.54 | -0.16 | -28.68% |
| Q1 2021 Q2Q % growth | -0.54 | -0.36 | -0.18 | -49.13% |
| Q4 2020 Q2Q % growth | -1.37 | -0.50 | -0.87 | -174.11% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A |
| Revenue | N/A | N/A | N/A | N/A |